News
ANI Pharmaceuticals (NASDAQ:ANIP) lost ~8% in the premarket on Wednesday after the company announced a failure in a clinical ...
14h
Clinical Trials Arena on MSNANI Pharmaceuticals reports outcomes from diabetic macular oedema trialThe trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...
In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...
Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results